←
BioAscend2,365 posts
BioAscend avatar

BioAscend

@BioAscend

Bio Ascend is an independent medical education company helping #oncology & hematology health care providers translate innovative science into clinical practice.

◷ Joined May 2016▧ 1,601 Photos and videos
BioAscend avatar
BioAscend@BioAscend·Nov 14

✨ Registration Open! ✨ We Go Together: The Power of Allyship in Advancing Women in GI Oncology Join GI oncology leaders for a moderated conversation on sponsorship, allyship, and building a more inclusive future for the field. 🗣️ Moderated by Drs. Pamela Kunz & Aparna Parikh 📍 San Francisco Marriott Marquis, Salons 2-6 📅 Thursday, January 21, 2027 🌟 Register today: loom.ly/RONGIJ8 #GIOncology #OncologyLeadership #Allyship

Post attachment
BioAscend avatar
BioAscend@BioAscend·Nov 7

Are antibody-drug conjugates (ADCs) truly transformational in NSCLC?

BioAscend avatar
BioAscend@BioAscend·Nov 7

MRD status should guide adjuvant therapy in patients with advanced lung cancer.

BioAscend avatar
BioAscend@BioAscend·Nov 7

The multidisciplinary team case panel discussion at #ALCS2026 convenes to discuss the role of all clinicians in the care of lung cancer

Post attachment
BioAscend avatar
BioAscend@BioAscend·Nov 7

It's the 20th anniversary of the Atlanta Lung Cancer Symposium! To mark this special occasion for #ALCS2026 @DrRoyHerbst is kicking off the meeting by giving a Keynote Presentation on the therapeutic revolution of early-stage NSCLC.

Post attachment
BioAscend avatar
BioAscend@BioAscend·Oct 21

🚨 Spotlight on Targeted Therapy in Advanced NSCLC II & Rare Thoracic Malignancies at #ALCS2026! 🚨 From HER2 to ROS1 to brain metastases, Plenary 4 goes deep on the drivers and rare cases shaping the next frontier of lung cancer care. Here’s a sneak peek at the key topics we'll unpack: ✳️ HER2-Mutated NSCLC: New First-Line Therapy and Other Options ✳️ Targeting ALK and Managing Resistance ✳️ ROS1 Fusion: Novel Agents and New Insights ✳️ Beyond the Big Drivers: Targeting RET, MET, and BRAF ✳️ Brain Metastases in NSCLC: Rethinking Management in the Targeted Therapy Era Register today: loom.ly/lVR_I5k #LungCancer #LCSM #OncologyEducation #NSCLC #TargetedTherapy #RareCancers

Post attachment
BioAscend avatar
BioAscend@BioAscend·Oct 12

🚨 Spotlight on Targeted Therapy in Advanced NSCLC at #ALCS2026! 🚨 The targeted therapy landscape is moving fast, and Plenary 3 is where we break it all down. Here’s a sneak peek at the key topics we’ll unpack: ✳️ EGFR-Mutated NSCLC: Common and Exon 20 Insertion Mutations ✳️ KRAS-Mutated NSCLC: The Next Targeted Therapy Frontier ✳️ Are ADCs Truly Transformational in NSCLC? Expert Debate Register today: loom.ly/lVR_I5k #LungCancer #LCSM #OncologyEducation #NSCLC #TargetedTherapy

Post attachment
BioAscend avatar
BioAscend@BioAscend·Sep 30

🚨 Spotlight on Advanced NSCLC & SCLC at #ALCS2026! 🚨 Join us for an in-depth Plenary Session exploring the latest in advanced lung cancer management, where the science is evolving and the debates are heating up. Here’s a sneak peek at the key topics we’ll unpack: ✳️ Immunotherapy for Advanced NSCLC: New Agents and Novel Combinations ✳️ Small Cell Lung Cancer: Expanding Options, More Hope ✳️ Locally Advanced NSCLC: Have We Hit the Ceiling? ✳️ MRD Status Should Guide Adjuvant Therapy — Expert Debate Register today: loom.ly/lVR_I5k #LungCancer #LCSM #OncologyEducation #NSCLC #SCLC

Post attachment